EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

High-Potency Depigmenting Mask Delivered via 1,927-nm Fractional Laser in Refractory Melasma: A Pilot Case Series

Jaime Piquero-Casals, Juan Francisco Mir-Bonafé, Eduardo Rozas-Muñoz, Vanesa Piquero-Casals, Daniel Morgado-Carrasco

Case Reports in Dermatology · 08.06.2026 · 18 (1) · 438-444

DOI: 10.1159/000552673 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Dermatology, online erschienen am 08.06.2026. Verfasst von Jaime Piquero-Casals und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Aesthetic Dermatology and Laser, Dermacentric Health & Aesthetics, Barcelona, Spain. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Melasma is a chronic, relapsing hyperpigmentation disorder and may remain refractory despite multiple topical agents and procedural approaches. Case Presentation: We report a case series of six women with Fitzpatrick skin types III–V and longstanding, treatment-resistant facial melasma managed with a multimodal protocol consisting of (1) a 16-week home regimen (twice-daily depigmenting cosmeceutical serum and daily high-protection sunscreen) and (2) two sessions of low-energy, low-density 1,927-nm fractional thulium laser at 4-week intervals, immediately followed by laser-assisted delivery of a compounded depigmenting mask (hydroquinone, retinoic acid, kojic acid, triamcinolone acetonide, vitamins C and E). Clinical response was assessed using the Melasma Severity Scale (MSS), standardized photography, and patient satisfaction. At week 16, all patients improved: 4 achieved >75% clinical improvement and 2 achieved 50–75% improvement, with high satisfaction and no significant adverse events beyond transient darkening and mild desquamation. Clinical benefits remained stable 12 weeks after the final laser session.

Conclusion

This case series suggests that 1,927-nm fractional thulium laser-assisted delivery of a high-potency depigmenting compound, supported by topical priming and strict photoprotection, may be a feasible option for selected patients with refractory melasma.

Schlagwörter

Stichwörter der Autor:innen

1,927-nm thulium laserChemical peelsCosmeceuticalsLaser-assisted drug deliveryRefractory melasma

Autor:innen und Institutionen

  • Department of Aesthetic Dermatology and Laser, Dermacentric Health & Aesthetics, Barcelona, Spain.
  • Department of Dermatology, Hospital Son Llàtzer, Palma de Mallorca, Spain.
  • Department of Dermatology, Hospital San Pablo, Coquimbo, Chile.
  • Department of Dermatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.

Zitieren

APA

Piquero-Casals, J., Mir-Bonafé, J. F., Rozas-Muñoz, E., Piquero-Casals, V., & Morgado-Carrasco, D. (2026). High-Potency Depigmenting Mask Delivered via 1,927-nm Fractional Laser in Refractory Melasma: A Pilot Case Series. Case Reports in Dermatology, 18(1), 438-444. https://doi.org/10.1159/000552673

Vancouver

Piquero-Casals J, Mir-Bonafé JF, Rozas-Muñoz E, Piquero-Casals V, Morgado-Carrasco D. High-Potency Depigmenting Mask Delivered via 1,927-nm Fractional Laser in Refractory Melasma: A Pilot Case Series. Case Reports in Dermatology. 2026;18(1):438-444. doi:10.1159/000552673

BibTeX
@article{PiqueroCasals2026,
  author = {Piquero-Casals, Jaime and Mir-Bonafé, Juan Francisco and Rozas-Muñoz, Eduardo and Piquero-Casals, Vanesa and Morgado-Carrasco, Daniel},
  title = {High-Potency Depigmenting Mask Delivered via 1,927-nm Fractional Laser in Refractory Melasma: A Pilot Case Series},
  journal = {Case Reports in Dermatology},
  year = {2026},
  volume = {18},
  number = {1},
  pages = {438--444},
  doi = {10.1159/000552673}
}
Kostenlos starten →